Letter to the Industry: Clarifying FTC’s Stance on Structure-Function Claim Substantiation

In the wake of recent trade press confusion, KGK Science sets the record straight on FTC’s Health Products Compliance Guidance. This letter critically analyzes misleading interpretations around substantiation standards, including the use of randomized controlled trials (RCTs), the definition of structure-function claims, and the difference between FTC and FDA expectations. With clear insights and regulatory expertise, KGK provides reassurance that while terminology may shift, the evidentiary standard remains the same: competent and reliable scientific evidence.